The Swiss pharmaceutical Novartis has raised its expectations for the whole year. According to the company, market conditions in the pharmaceutical industry are attractive. Earlier, Novartis was faced with a weaker demand for his medication because fewer people visited a doctor during the coronacrisis, for example, treatments of skin and eye disorders. Novartis is now scraping off its forecasts for turnover and operating profit. Over the past period, sales increased by 1% to almost $ 12.3 billion compared to a year earlier. The operating profit increased by 2% to 2.4 billion dollars. Net profit fell by 5% to over $ 1.9 billion. According to Novartis, this has to do with legal costs. Novartis’s CEO Vas Narasimhan spoke of solid results despite the impact of the coronacrisis on drug demand. He said he was excited about the pipeline of products that the company is going to market like a remedy for multiple sclerosis.
